Teva Pharmaceutical Industries (TEVA) Gross Profit (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Gross Profit for 18 consecutive years, with $2.0 billion the latest figure, recorded in Q1 2026.

• Quarterly Gross Profit rose 5.06% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 billion (up 10.58% YoY) and the FY2025 annual result came in at $8.9 billion, up 10.84% from the prior year.
• Gross Profit slipped to $2.0 billion in Q1 2026 per TEVA's latest filing, from $2.7 billion in the prior quarter.
• Over the last five years, Gross Profit for TEVA reached as high as $2.7 billion in Q4 2025 and fell as low as $1.6 billion in Q1 2023.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2025 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit slipped 13.66% — and 2023, when it surged 36.5%.
• Year by year, Gross Profit stood at $1.8 billion in 2022, then soared by 36.5% to $2.4 billion in 2023, then fell by 12.21% to $2.1 billion in 2024, then gained by 25.22% to $2.7 billion in 2025, then decreased by 25.75% to $2.0 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $2.0 billion, $2.7 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.